Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Consensus Rating of “Buy” from Brokerages

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been assigned an average recommendation of “Buy” from the six analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $20.50.

TLX has been the subject of several research analyst reports. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Wedbush reissued an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Wednesday, September 23rd. Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, September 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a report on Friday, September 25th.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of TLX. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Telix Pharmaceuticals during the second quarter valued at about $1,731,000. Private Advisor Group LLC lifted its holdings in Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after buying an additional 128,070 shares during the period. XY Capital Ltd lifted its holdings in Telix Pharmaceuticals by 468.0% in the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after buying an additional 58,739 shares during the period. Bank of America Corp DE boosted its position in Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares in the last quarter. Finally, Lazard Asset Management LLC boosted its position in Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after acquiring an additional 39,400 shares in the last quarter.

Telix Pharmaceuticals Stock Down 1.6%

NASDAQ TLX opened at $10.55 on Monday. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $13.11. The business’s 50-day moving average is $11.40 and its 200 day moving average is $10.59.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its technologies are designed to help identify disease through medical imaging and, in some cases, deliver radiation directly to targeted cancer cells.

The company’s primary commercial product is Illuccix (kit for the preparation of gallium-68 gozetotide injection), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in adults with prostate cancer.